Targovax to present at DNB healthcare conference
Oslo, Norway, 13 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management will present a corporate overview at the following conference: DNB Nordic Healthcare conferenceDate: 14 December 2017Participants: Øystein Soug (CEO), Magnus Jäderberg (CMO) and Erik Wiklund (CFO)Presentation time: 09:30 CETVenue: DNB, Oslo The presentation will be available to download at www.targovax.com following these events. For further information, please contact: